Affilogic
Olivier Kitten is the Founder and CEO of Affilogic, a company established in February 2010 that specializes in developing custom affinity ligands for various applications including analytics, bioprocessing, in vitro diagnostics, in vivo imaging, and therapeutic uses. Prior to Affilogic, Olivier held positions as Coordinator at Atlantic Biotherapies from November 2005 to August 2009, Life Sciences Manager at Atlanpole from December 2002 to August 2009, COO at Atlangene Applications from January 2001 to December 2002, and Senior Scientist at Rhone-Poulenc Rorer Gencell from 1997 to 2001. Olivier Kitten completed a Ph.D. in Gene Transfer at Université de Rennes I from 1994 to 1997 and studied at CentraleSupélec from 1991 to 1993.
This person is not in any teams
Affilogic
Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule. Affilogic has designed Nanofitins® against 60+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (virus-like particles, bacteria, whole cells).